Amgen (AMGN) reported earnings per share (EPS) of $6.45 against an estimate of $5.79, and revenue of $10.37 billion against an estimate of $10.07 billion, both beats. In the after-hours session following the report, shares slipped 1.51% to $454.30 from a close of $461.26.
Source: Trades in the regular session and after hours, against the close · as of November 3, 2026 at 6:46 PM ET · Five-minute closes. Extended-hours trading is thin; the price can move a long way before the open.
| Measure | Reported | Estimate | Result |
|---|---|---|---|
| Earnings per share | $6.45 | $5.79 | Beat |
| Revenue | $10.37 billion | $10.07 billion | Beat |
Source: Company earnings report and sell-side analyst consensus estimates · as of November 3, 2026 at 6:46 PM ET · Reported after the close on Tuesday, November 3, 2026.
Against the quarters before
Amgen has topped both earnings per share (EPS) and revenue estimates in each of the last four quarters listed. In August 2026 it posted EPS of $6.29 against an expected $5.62, with revenue of $10.05 billion. In April 2026, EPS came in at $5.15 versus $4.77 expected, on revenue of $8.62 billion. February 2026 brought EPS of $5.29 against $4.73 expected, with revenue of $9.87 billion, and in November 2025 EPS reached $5.64 versus a $5.02 estimate, with revenue of $9.56 billion.
Source: Company earnings reports and the consensus estimates at the time
| Reported | EPS | Estimate | Revenue | EPS result |
|---|---|---|---|---|
| August 4, 2026 | $6.29 | $5.62 | $10.05 billion | Beat |
| April 30, 2026 | $5.15 | $4.77 | $8.62 billion | Beat |
| February 3, 2026 | $5.29 | $4.73 | $9.87 billion | Beat |
| November 4, 2025 | $5.64 | $5.02 | $9.56 billion | Beat |
Source: Company earnings reports and the consensus estimates at the time
How the stock took it
Despite the earnings and revenue beat, Amgen shares fell 1.51% in after-hours trading to $454.30, down from the prior close of $461.26. In the official earnings release carried by PR Newswire, chairman and chief executive officer Robert A. Bradway said the company "delivered another strong quarter," crediting its commercial portfolio, clinical progress and pipeline for giving the company confidence in sustained growth ahead. Investor's Business Daily noted that Amgen shares are up 41% this year and have been outperforming peers broadly.
| Measure | Value |
|---|---|
| Last close | $461.26 |
| Price | $454.30 |
| Change | -1.51% |
Source: Extended-hours trades against the regular close · as of November 3, 2026 at 6:46 PM ET · Extended-hours trading is thin; the price can move a long way before the open.
Who it buys from and sells to
Company filings list Omnicom Group, SolarWinds Corporation and ChemoCentryx as suppliers to Amgen, while Express Scripts, United Health Group and CVS appear as customers. This chain spans advertising services, software and clinical-stage biotechnology on the supply side, and major pharmacy benefit and health insurance networks on the customer side, reflecting how Amgen's products move from development through to patients.
| Company | Role | Stock | Last move |
|---|---|---|---|
| Omnicom Group | Supplier | OMC | -0.98% |
| Express Scripts | Customer | Not listed | — |
| United Health Group | Customer | Not listed | — |
| CVS | Customer | Not listed | — |
| SolarWinds Corporation | Supplier | Not listed | — |
| ChemoCentryx | Supplier | Not listed | — |
Source: Relationships named in company filings (Earnings call transcript; SEC 10-K annual report); stock quotes · as of November 3, 2026 at 6:46 PM ET · Named in filings; a neighbour's move is not evidence of a link to this report.